Research across Metabolic Dysfunction-Associated Steatohepatitis
Related studies from across the Metabolic Dysfunction-Associated Steatohepatitis family.
Network meta-analysis ranks FGF21 analogs and SGLT2 inhibitors highest for MASH fibrosis
New analysis shows SGLT2 inhibitors may help liver scarring improve in adults with fatty liver disease
A network meta-analysis of 34 trials found FGF21 analogs and SGLT2 inhibitors ranked highest for improving liver fibrosis in MASH, with GLP-…
A large review of trials found SGLT2 inhibitors ranked highest for reducing liver scarring. These drugs also showed good safety and balanced…
Narrative review explores immunometabolic networks in MASH and MASLD
Future treatments for fatty liver disease may use personalized networks to guide care
This narrative review discusses metabolic dysfunction-associated steatohepatitis (MASH) and steatotic liver disease (MASLD), focusing on imm…
New ideas for treating fatty liver disease focus on personalized networks and multi-target approaches to guide future drug development.
Narrative review explores macrophage reprogramming for liver fibrosis and MASH
Scientists explore new ways to reprogram liver cells to heal damaged tissue and stop scarring
This narrative review summarizes macrophage reprogramming strategies for liver fibrosis and MASH. Approaches include gene modulation, pharma…
A recent review looks at fresh methods to change how liver immune cells behave. These changes could help heal liver scarring and improve hea…
Review of triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease
New Hope for Fatty Liver Disease Targets Hidden Triglyceride Problem
This narrative review synthesizes evidence on triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease. …
• Lowering triglycerides may directly heal fatty liver damage • Helps millions with metabolic syndrome and stubborn liver fat • Most treatme…
Network meta-analysis of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis
New therapies show promise for liver disease without cirrhosis
This network meta-analysis of 12,787 adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis from phase 2-3 trials evalua…
Treatments targeting metabolism and insulin sensitivity helped more people with early liver disease than placebo, based on a large review of…
Meta-analysis of placebo responses in metabolic dysfunction-associated steatohepatitis trials reveals modest natural resolution rates and low progression risk
New meta-analysis shows how many patients improve on placebo for MASH
This systematic review and meta-analysis examined placebo outcomes in patients with metabolic dysfunction-associated steatohepatitis.
This analysis of 6,880 patients reveals natural improvement rates in metabolic dysfunction-associated steatohepatitis when no active drug is…
Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity
Weight-loss drugs and surgery may clear fatty liver disease in adults with high BMI
This systematic review and network meta-analysis evaluates interventions for metabolic dysfunction-associated steatotic liver disease and st…
A new analysis suggests tirzepatide, semaglutide, and surgery might help resolve fatty liver disease without worsening scarring in adults wi…
Systematic review and meta-analysis evaluates ML and DL models for diagnosing MASH and fibrosis
AI models help doctors spot liver disease with high accuracy
This systematic review and meta-analysis of 106 studies assessed machine learning (ML) and deep learning (DL) models for diagnosing metaboli…
New computer tools can diagnose fatty liver disease and scarring with impressive accuracy. This review analyzed data from many studies to se…
Pathophysiological review explores platelet activity and antiplatelet agents in metabolic dysfunction-associated steatohepatitis and steatotic liver disease
New Role for Blood Cells in Fatty Liver Disease Could Change Treatment
This pathophysiological review examines the role of platelet activity and antiplatelet agents in metabolic dysfunction-associated steatohepa…
Understanding how blood cells affect your liver could lead to new, targeted treatments for a dangerous liver condition.
Transcriptomic signature distinguishes MASL from MASH using neural network model
New Blood Test Could Spot Hidden Liver Damage Before It’s Too Late
This observational study combined transcriptomic and single-cell analysis with an artificial neural network to differentiate metabolic…
This research could finally give doctors a simple blood test to tell the difference between harmless fat buildup and dangerous liver scarrin…
Observational study links semaglutide dose and weight loss to lower liver disease risk
Study links semaglutide use to lower risk of several liver conditions in patients with liver disease
This observational study from a real-world federated EHR network analyzed 6,734 patients with liver disease.
Higher semaglutide doses and greater weight loss were linked to lower risks of steatohepatitis, alcoholic liver disease, and death in patien…
Narrative review synthesizes evidence on NAFLD, NASH, and viral hepatitis management without reported trial data
Your Liver Has an Immune Army — and It Can Turn Against You
This narrative review addresses management considerations for nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH),…
Your liver's own immune cells can turn on itself to cause permanent scarring, but scientists are now mapping these cells to stop the damage …